SUPN
Income statement / Annual
Last year (2025), Supernus Pharmaceuticals Inc's total revenue was $718.95 M,
an increase of 8.63% from the previous year.
In 2025, Supernus Pharmaceuticals Inc's net income was -$38.55 M.
See Supernus Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$718.95 M |
$661.82 M |
$607.52 M |
$667.24 M |
$579.78 M |
$520.40 M |
$392.76 M |
$408.90 M |
$302.24 M |
$215.00 M |
| Cost of Revenue |
$74.56 M
|
$77.91 M
|
$83.78 M
|
$87.22 M
|
$75.06 M
|
$52.46 M
|
$16.66 M
|
$15.36 M
|
$15.22 M
|
$11.99 M
|
| Gross Profit |
$644.39 M
|
$583.91 M
|
$523.74 M
|
$580.02 M
|
$504.71 M
|
$467.94 M
|
$376.10 M
|
$393.54 M
|
$287.02 M
|
$203.02 M
|
| Gross Profit Ratio |
0.9
|
0.88
|
0.86
|
0.87
|
0.87
|
0.9
|
0.96
|
0.96
|
0.95
|
0.94
|
| Research and Development Expenses |
$106.24 M
|
$108.80 M
|
$91.59 M
|
$74.55 M
|
$90.47 M
|
$75.96 M
|
$69.10 M
|
$89.21 M
|
$49.58 M
|
$42.79 M
|
| General & Administrative Expenses |
$196.91 M
|
$247.28 M
|
$236.66 M
|
$109.43 M
|
$105.05 M
|
$65.92 M
|
$117.63 M
|
$116.59 M
|
$104.11 M
|
$84.11 M
|
| Selling & Marketing Expenses |
$288.65 M
|
$88.50 M
|
$99.70 M
|
$267.79 M
|
$199.71 M
|
$134.75 M
|
$40.80 M
|
$43.30 M
|
$33.80 M
|
$21.90 M
|
| Selling, General & Administrative Expenses |
$485.56 M
|
$335.78 M
|
$336.36 M
|
$377.22 M
|
$304.76 M
|
$200.68 M
|
$158.43 M
|
$159.89 M
|
$137.91 M
|
$106.01 M
|
| Other Expenses |
$89.46 M
|
$57.67 M
|
$101.06 M
|
$82.12 M
|
$23.46 M
|
$17.60 M
|
$0.00
|
$0.00
|
$0.00
|
-$15.00 K
|
| Operating Expenses |
$681.25 M
|
$502.25 M
|
$529.01 M
|
$533.89 M
|
$418.69 M
|
$294.24 M
|
$227.52 M
|
$249.10 M
|
$187.48 M
|
$148.80 M
|
| Cost And Expenses |
$755.82 M
|
$580.15 M
|
$612.79 M
|
$621.11 M
|
$493.75 M
|
$346.70 M
|
$244.18 M
|
$264.45 M
|
$202.70 M
|
$160.79 M
|
| Interest Income |
$13.25 M
|
$16.20 M
|
$10.45 M
|
$21.69 M
|
$10.57 M
|
$18.70 M
|
$21.62 M
|
$13.84 M
|
$2.65 M
|
$1.48 M
|
| Interest Expense |
$0.00
|
$0.00
|
$2.42 M
|
$7.07 M
|
$23.42 M
|
$23.75 M
|
$22.71 M
|
$18.11 M
|
$1.57 M
|
$5.09 M
|
| Depreciation & Amortization |
$91.56 M
|
$80.41 M
|
$84.86 M
|
$85.54 M
|
$32.60 M
|
$18.14 M
|
$10.23 M
|
$7.06 M
|
$8.13 M
|
$2.40 M
|
| EBITDA |
$42.53 M |
$178.28 M |
$90.04 M |
$153.36 M |
$129.19 M |
$210.54 M |
$180.42 M |
$151.51 M |
$107.67 M |
$56.62 M |
| EBITDA Ratio |
0.06
|
0.27
|
0.15
|
0.23
|
0.22
|
0.4
|
0.46
|
0.37
|
0.36
|
0.26
|
| Operating Income Ratio |
-0.05
|
0.12
|
-0.01
|
0.07
|
0.15
|
0.33
|
0.38
|
0.35
|
0.33
|
0.25
|
| Total Other Income/Expenses Net |
-$12.17 M
|
$16.20 M
|
$8.04 M
|
$14.62 M
|
-$12.85 M
|
-$5.05 M
|
-$1.08 M
|
-$4.27 M
|
$1.08 M
|
-$3.85 M
|
| Income Before Tax |
-$49.03 M
|
$97.87 M
|
$2.77 M
|
$60.74 M
|
$73.18 M
|
$168.65 M
|
$147.49 M
|
$140.18 M
|
$100.62 M
|
$50.37 M
|
| Income Before Tax Ratio |
-0.07
|
0.15
|
0
|
0.09
|
0.13
|
0.32
|
0.38
|
0.34
|
0.33
|
0.23
|
| Income Tax Expense |
-$10.48 M
|
$24.01 M
|
$1.45 M
|
$32.00 K
|
$19.75 M
|
$41.70 M
|
$34.43 M
|
$29.18 M
|
$43.33 M
|
-$40.85 M
|
| Net Income |
-$38.55 M
|
$73.87 M
|
$1.32 M
|
$60.71 M
|
$53.42 M
|
$126.95 M
|
$113.06 M
|
$110.99 M
|
$57.28 M
|
$91.22 M
|
| Net Income Ratio |
-0.05
|
0.11
|
0
|
0.09
|
0.09
|
0.24
|
0.29
|
0.27
|
0.19
|
0.42
|
| EPS |
-0.68 |
1.34 |
0.0241 |
1.13 |
1.01 |
2.41 |
2.16 |
2.13 |
1.13 |
1.84 |
| EPS Diluted |
-0.68 |
1.32 |
0.0237 |
1.04 |
0.98 |
2.36 |
2.1 |
2.05 |
1.08 |
1.76 |
| Weighted Average Shares Out |
$56.45 M
|
$55.10 M
|
$54.54 M
|
$53.67 M
|
$53.10 M
|
$52.62 M
|
$52.41 M
|
$51.99 M
|
$50.76 M
|
$49.47 M
|
| Weighted Average Shares Out Diluted |
$56.45 M
|
$55.96 M
|
$55.51 M
|
$61.68 M
|
$54.36 M
|
$53.69 M
|
$53.82 M
|
$54.10 M
|
$53.30 M
|
$51.71 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
